(Q31729104)

3 July 2017

1 reference

title

Diabetes: statins, fibrates, or both? (English)

1 reference

3 July 2017

Farnier M

1

1 reference

3 July 2017

Picard S

series ordinal

2

1 reference

3 July 2017

publication date

1 January 2001

1 reference

Current Atherosclerosis Reports

3 July 2017

published in

1 reference

3 July 2017

volume

3

1 reference

3 July 2017

issue

1

1 reference

3 July 2017

page(s)

19-28

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-001-0006-y

3 July 2017

exact match

0 references

cites work

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS11883-001-0006-Y

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-001-0006-Y

Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-001-0006-Y

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-001-0006-Y

Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-001-0006-Y

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-001-0006-Y

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-001-0006-Y

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

12 December 2020

Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial

1 reference

12 December 2020

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

12 December 2020

HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients

1 reference

12 December 2020

Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus.

1 reference

12 December 2020

The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group.

1 reference

12 December 2020

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?

1 reference

12 December 2020

Postprandial lipoprotein clearance in type 2 diabetes: fenofibrate effects.

1 reference

12 December 2020

Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group

1 reference

12 December 2020

A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia

1 reference

12 December 2020

Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.

1 reference

12 December 2020

Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics

1 reference

12 December 2020

Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study

1 reference

12 December 2020

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

12 December 2020

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

1 reference

12 December 2020

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

1 reference

12 December 2020

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment

1 reference

12 December 2020

Intensive lipid-lowering strategy in patients with diabetes mellitus

1 reference

12 December 2020

Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies.

1 reference

12 December 2020

Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance.

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Role of fibrates in the management of hypertriglyceridemia

1 reference

12 December 2020

Lipoprotein concentrations and carotid atherosclerosis by diabetes status: results from the Insulin Resistance Atherosclerosis Study

1 reference

12 December 2020

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.

1 reference

12 December 2020

Low-density lipoprotein-independent effects of statins

1 reference

12 December 2020

Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolaemia. Hyperlipidaemia in Diabetes Mellitus investigators

1 reference

12 December 2020

Stimulation of bone formation in vitro and in rodents by statins

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

1 reference

12 December 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

12 December 2020

Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors. Hyogo Simvastatin Study Group.

1 reference

12 December 2020

Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group

1 reference

12 December 2020

Effects of simvastatin on fasting and postprandial triglyceride-rich lipoproteins in patients with type I diabetes mellitus.

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus

1 reference

12 December 2020

Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Rates of progression of coronary calcium by electron beam tomography

1 reference

12 December 2020

Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels

1 reference

12 December 2020

Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.

1 reference

12 December 2020

Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study

1 reference

12 December 2020

Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy

1 reference

12 December 2020

Effect of simvastatin in patients with type I (insulin-dependent) diabetes mellitus and hypercholesterolemia

1 reference

12 December 2020

Management of dyslipidemia in adults with diabetes

1 reference

12 December 2020

Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

1 reference

12 December 2020

Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

10.1007/S11883-001-0006-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

3 July 2017

1025892451

0 references

1 reference